Predicting surgical outcomes in single-port robot-assisted partial nephrectomy: external validation and comparative analysis of PADUA, RENAL, and SPARE scores - Scorecard - MDSpire
Advertisement
Predicting surgical outcomes in single-port robot-assisted partial nephrectomy: external validation and comparative analysis of PADUA, RENAL, and SPARE scores
Clinical Scorecard: Evaluating Surgical Outcomes in Single-Port Robot-Assisted Partial Nephrectomy: External Validation and Comparative Study of PADUA, RENAL, and SPARE Scoring Systems
Use of anatomical nephrometry scores (PADUA, RENAL, SPARE) to predict surgical outcomes including Trifecta achievement
Target Population
Patients with solitary ≤ cT2 renal tumors without lymph-node or distant metastases
Care Setting
Surgical treatment in academic institutions using da Vinci SP robotic platform
Key Highlights
SP-RAPN with retroperitoneal approach provides direct renal hilum access without bowel mobilization
PADUA, RENAL, and SPARE nephrometry scores quantify tumor complexity and predict perioperative outcomes
Trifecta achievement (negative margins, no complications, WIT ≤ 25 min) used as primary surgical outcome measure
Guideline-Based Recommendations
Diagnosis
Preoperative CT or MRI within 90 days prior to surgery for tumor assessment
Use of standardized nephrometry scores (PADUA, RENAL, SPARE) for anatomical tumor evaluation
Management
Perform SP-RAPN via retroperitoneal or transperitoneal approach using da Vinci SP system
Surgical planning guided by nephrometry scores to anticipate complexity and morbidity
Surgeon discretion on enucleoresection versus tumor enucleation techniques
Monitoring & Follow-up
Record intraoperative variables including WIT, estimated blood loss, operative time, and use of vascular clamping
Monitor perioperative complications graded by Clavien–Dindo classification within 90 days post-surgery
Assess renal function changes pre- and post-operatively via estimated glomerular filtration rate
Risks
Consider patient comorbidities such as hypertension, diabetes, and ASA score in surgical risk assessment
Recognize moderate interobserver variability in nephrometry scoring; use consensus for ambiguous cases
Exclude patients with solitary kidney, end-stage renal disease, or recurrent renal cell carcinoma from SP-RAPN
Patient & Prescribing Data
211 patients with solitary ≤ cT2 renal tumors undergoing SP-RAPN
Majority male, median age 60, with common comorbidities including hypertension and diabetes; most tumors intermediate complexity by PADUA and low complexity by RENAL and SPARE scores
Clinical Best Practices
Use nephrometry scores to standardize tumor complexity assessment and guide surgical planning
Employ retroperitoneal approach preferentially in SP-RAPN for direct renal hilum access
Achieve Trifecta outcomes by ensuring negative margins, minimizing complications, and limiting warm ischemia time to ≤ 25 minutes